Dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome

Hypertension

Volumn 64, Issue 4, 2014, Pages 709-716

  Laurent, Stephane ^a,b   Boutouyrie, Pierre ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

Author keywords

Antihypertensive agents; Aorta; Arteries; Blood pressure; Compliance; Hypertension; Randomized controlled trial

Indexed keywords

ANTIHYPERTENSIVE AGENT; IMIDAZOLE DERIVATIVE; OLMESARTAN; TETRAZOLE DERIVATIVE;

ADULT; ARTERIAL STIFFNESS; BLOOD PRESSURE; CAROTID ARTERY; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; HUMAN; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CAROTID ARTERIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PULSE WAVE ANALYSIS; TETRAZOLES; TREATMENT OUTCOME; VASCULAR STIFFNESS;

EID: 84914666833     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03282     Document Type: Article

References (32)

1. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H; European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: Methodological issues and clinical applications. Eur Heart J. 2006;27: 2588-2605.
2. Boutouyrie P, Lacolley P, Briet M, Regnault V, Stanton A, Laurent S, Mahmud A. Pharmacological modulation of arterial stiffness. Drugs. 2011;71: 1689-1701.
3. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25: 932-943.
4. Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial stiffness. Hypertension. 2005;45: 1050-1055.
5. Ait-Oufella H, Collin C, Bozec E, Laloux B, Ong KT, Dufouil C, Boutouyrie P, Laurent S. Long-term reduction in aortic stiffness: A 5.3-year follow-up in routine clinical practice. J Hypertens. 2010;28: 2336-2341.
6. Ong KT, Delerme S, Pannier B, Safar ME, Benetos A, Laurent S, Boutouyrie P; investigators. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: A meta-analysis of individual data in 294 patients. J Hypertens. 2011;29: 1034-1042.
7. Tropeano AI, Boutouyrie P, Pannier B, Joannides R, Balkestein E, Katsahian S, Laloux B, Thuillez C, Struijker-Boudier H, Laurent S. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension. 2006;48: 80-86.
8. Mitchell GF, Dunlap ME, Warnica W, Ducharme A, Arnold JM, Tardif JC, Solomon SD, Domanski MJ, Jablonski KA, Rice MM, Pfeffer MA; Prevention of Events with Angiotensin-Converting Enzyme Inhibition Investigators. Long-term trandolapril treatment is associated with reduced aortic stiffness: The prevention of events with angiotensinconverting enzyme inhibition hemodynamic substudy. Hypertension. 2007;49: 1271-1277.
9. Mitchell GF, Izzo JL Jr, Lacourcière Y, Ouellet JP, Neutel J, Qian C, Kerwin LJ, Block AJ, Pfeffer MA. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: Results of the conduit hemodynamics of omapatrilat international research study. Circulation. 2002;105: 2955-2961.
10. Nakamura T, Fujii S, Hoshino J, Saito Y, Mizuno H, Saito Y, Kurabayashi M. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients. Hypertens Res. 2005;28: 937-943.
11. Edwards NC, Ferro CJ, Kirkwood H, Chue CD, Young AA, Stewart PM, Steeds RP, Townend JN. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. Am J Cardiol. 2010;106: 1505-1511.
12. Fliser D, Buchholz K, Haller H; EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110: 1103-1107.
13. Schram MT, Henry RM, van Dijk RA, Kostense PJ, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Westerhof N, Stehouwer CD. Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: The Hoorn Study. Hypertension. 2004;43: 176-181.
14. Scuteri A, Najjar SS, Muller DC, Andres R, Hougaku H, Metter EJ, Lakatta EG. Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol. 2004;43: 1388-1395.
15. Czernichow S, Bertrais S, Blacher J, Oppert JM, Galan P, Ducimetière P, Hercberg S, Safar M, Zureik M; SU.VI.MAX. Vascular Study. Metabolic syndrome in relation to structure and function of large arteries: A predominant effect of blood pressure. A report from the SU.VI.MAX. Vascular Study. Am J Hypertens. 2005;18(9 Pt 1): 1154-1160.
16. Ferreira I, Henry RM, Twisk JW, van Mechelen W, Kemper HC, Stehouwer CD; Amsterdam Growth and Health Longitudinal Study. The metabolic syndrome, cardiopulmonary fitness, and subcutaneous trunk fat as independent determinants of arterial stiffness: The Amsterdam Growth and Health Longitudinal Study. Arch Intern Med. 2005;165: 875-882.
17. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102: 42-47.
18. Martinez-Martin FJ, Rodriguez-Rosas H, Peiro-Martinez I, Soriano- Perera P, Pedrianes-Martin P, Comi-Diaz C. Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: The OLAS study. J Hum Hypertens. 2011;25: 346-353.
19. Denke MA, Pasternak RC. Defining and Treating the Metabolic Syndrome: A Primer from the Adult Treatment Panel III. Curr Treat Options Cardiovasc Med. 2001;3: 251-253.
20. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-A new worldwide definition. Lancet. 2005;366: 1059-1062.
21. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28: 1462-1536.
22. Ong KT, Perdu J, De Backer J, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: A prospective randomised, open, blinded-endpoints trial. Lancet. 2010;376: 1476-1484.
23. Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, Filipovsky J, Huybrechts S, Mattace-Raso FU, Protogerou AD, Schillaci G, Segers P, Vermeersch S, Weber T; Artery Society; European Society of Hypertension Working Group on Vascular Structure and Function; European Network for Noninvasive Investigation of Large Arteries. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30: 445-448.
24. Breslow NE, Clayton DG. Approximate inference in Generalized Linear Mixed Models. J Am Stat Assoc. 1993;88: 9-25.
25. Osto E, Coppolino G, Volpe M, Cosentino F. Restoring the dysfunctional endothelium. Curr Pharm Des. 2007;13: 1053-1068.
26. Arao T, Okada Y, Mori H, Nishida K, Tanaka Y. Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension. Endocr J. 2013;60: 563-570.
27. Miyoshi T, Hirohata A, Usui S, Yamamoto K, Murakami T, Komatsubara I, Kusachi S, Ohe T, Nakamura K, Ito H. Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: Results from the OLIVUS trial. Heart Vessels. 2014;29: 178-185.
28. Nakayama S, Watada H, Mita T, Ikeda F, Shimizu T, Uchino H, Fujitani Y, Hirose T, Kawamori R. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res. 2008;31: 7-13.
29. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int. 2005;68: 1190-1198.
30. Hollenberg NK, Parving HH, Viberti G, Remuzzi G, Ritter S, Zelenkofske S, Kandra A, Daley WL, Rocha R. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007;25: 1921-1926.
31. Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: A double-blind, randomized, prospective study. J Am Soc Nephrol. 2005;16: 3038-3045.
32. Burgess E, Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S; SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol. 2009;20: 893-900.